Nikrahan Gholam Reza, Laferton Johannes A C, Asgari Karim, Kalantari Mehrdad, Abedi Mohammad Reza, Etesampour Ali, Rezaei Abbas, Suarez Laura, Huffman Jeff C
Department of Psychology, University of Isfahan, Isfahan, Iran; Department of Psychology, Islamic Azad University of Borujen, Borujen, Iran.
Department of Psychiatry, Brigham and Women's Hospital, Boston, MA; Department of Psychiatry, Harvard Medical School, Boston, MA.
Psychosomatics. 2016 Jul-Aug;57(4):359-68. doi: 10.1016/j.psym.2016.02.007. Epub 2016 Feb 24.
Among cardiac patients, positive psychologic factors are consistently linked with superior clinical outcomes and improvement in key markers of inflammation and hypothalamic-pituitary-adrenal axis functioning. Further, positive psychology interventions (PPI) have effectively increased psychologic well-being in a wide variety of populations. However, there has been minimal study of PPIs in cardiac patients, and no prior study has evaluated their effect on key prognostic biomarkers of cardiac outcome. Accordingly, we investigated the effect of 3 distinct PPIs on risk biomarkers in cardiac patients.
In an exploratory trial, 69 patients with recent coronary artery bypass graft surgery or percutaneous intervention were randomized to (1) one of three 6-week in-person PPIs (based on the work of Seligman, Lyubomirsky, or Fordyce) or (2) a wait-list control group. Risk biomarkers were assessed at baseline, postintervention (7 weeks), and at 15-week follow-up. Between-group differences in change from baseline biomarker levels were examined via random effects models.
Compared with the control group, participants randomized to the Seligman (B = -2.06; p = 0.02) and Fordyce PPI (B = -1.54; p = 0.04) had significantly lower high-sensitivity C-reactive protein levels at 7 weeks. Further, the Lyubomirsky PPI (B = -245.86; p = 0.04) was associated with a significantly lower cortisol awakening response at 7 weeks when compared with control participants. There were no other significant between-group differences.
Despite being an exploratory pilot study with multiple between-group comparisons, this initial trial offers the first suggestion that PPIs might be effective in reducing risk biomarkers in high-risk cardiac patients.
在心脏病患者中,积极的心理因素一直与更好的临床结果以及炎症和下丘脑 - 垂体 - 肾上腺轴功能关键指标的改善相关。此外,积极心理学干预(PPI)已在广泛人群中有效提高了心理健康水平。然而,针对心脏病患者的PPI研究极少,且此前尚无研究评估其对心脏结局关键预后生物标志物的影响。因此,我们研究了三种不同的PPI对心脏病患者风险生物标志物的影响。
在一项探索性试验中,69例近期接受冠状动脉搭桥手术或经皮介入治疗的患者被随机分为(1)三种为期6周的面对面PPI之一(基于塞利格曼、柳博米尔斯基或福代斯的研究)或(2)等待名单对照组。在基线、干预后(7周)和15周随访时评估风险生物标志物。通过随机效应模型检查组间生物标志物水平相对于基线变化的差异。
与对照组相比,随机分配到塞利格曼PPI组(B = -2.06;p = 0.02)和福代斯PPI组(B = -1.54;p = 0.04)的参与者在7周时高敏C反应蛋白水平显著更低。此外,与对照组参与者相比,柳博米尔斯基PPI组(B = -245.86;p = 0.04)在7周时的皮质醇觉醒反应显著更低。组间无其他显著差异。
尽管这是一项有多个组间比较的探索性初步试验,但该初始试验首次表明PPI可能对降低高危心脏病患者的风险生物标志物有效。